Researchers from both Singapore and Sweden have, within a day of each other, announced their own blood tests for Alzheimer's disease.
A computer-assisted diagnostic procedure helps physicians detect the growth of low-grade brain tumours earlier and at smaller volumes than visual comparison alone.
US scientists have found a way to differentiate the subset of patients with prostate cancer who require more aggressive management and treatment.
European researchers have found a way to identify hospital patients with suspected sepsis infection who may suffer from subsequent disease progression.
Thermo Fisher Scientific has entered into a collaboration with NX Prenatal to develop proteomics assays to monitor foetal health in utero and assess the risk of adverse outcomes.
Swedish scientists have shown how a blood test can reveal whether there is accelerating nerve cell damage in the brain.
The humble breath test can now do a lot more than detect if you've had too much to drink, with scientists all over the world developing breath tests for gut-based diseases.
A popular smartphone application, designed to measure heart rate using the phone's built-in camera, may help detect diabetes.
Researchers have revealed how origami-style folded paper, prepared with a printer and a hotplate, has detected malaria with 98% sensitivity in infected participants in Uganda.
Ebola virus may have re-emerged in a woman a year after she survived an acute infection, potentially leading to the infection of her husband and two of their sons.
Australian researchers have developed what is claimed to be the world's first blood test capable of detecting melanoma in its early stages.
Upstream Medical Technologies has developed a biomarker-based diagnostic test to rule out the risk of imminent heart attack for the significant number of people presenting at hospital with chest pain.
University of Leicester experts in association with the spin-off company MIP Diagnostics have developed polymeric materials with molecular recognition capabilities which hold the potential to outperform natural antibodies in various diagnostic applications.
Laboratory professionals must have detailed clinical information to make decisions on the most effective testing for patients.
Technology co-developed at the Universities of Oxford and Sao Paulo State University will be commercialised by spinout company Oxford Impedance Diagnostics (OID), offering the potential for the development of ultrasensitive fast diagnostic tests for a range of diseases.